Inflammatory acne Skin Diseases Acne Vulgaris
Conditions
Interventions
Hy-CBD Anti-Acne Gel, formulated with 3% w/w CBD-loaded HA-pNIPAM nanogel, was developed by the Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. This product is designe
Hy-CBD Anti-Acne Gel
Sponsors
NABSOLUTE CO., LTD
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Subject having inflammatory acnes on face.
Exclusion criteria
Exclusion criteria: For women: pregnant or nursing woman or woman planning to get pregnant during the study Cutaneous pathology on the study zone (eczema, etc) Subject has history of allergy to cosmetic products Retinoids during the six previous months of the study Acne treatment (except retinoids) since less than one month Any change in hormonal treatment (including contraceptive) during the three previous months of the study Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous acceptability/efficacy of the study product Subject went through dermatologist treatments or procedures within 2-month period before the study start Subject having undergone a surgery under general anesthesia within the previous month Excessive exposure to sunlight or UV-rays within the previous month Subject enrolled in another clinical trial during the study period Subject considered by the investigator to be likely not compliant to the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduce condition of inflammatory acne After 2 and 7 days of use the product Clinical scoring and measurement size using a vernier calliper by the dermatologist | — |
Secondary
| Measure | Time frame |
|---|---|
| Cutaneous acceptability After 2 and 7 days of use the product Clinical signs observed Functional and physical signs reported | — |
Countries
Thailand
Contacts
Public ContactSujittra Sombuntham
Dermscan Asia
Outcome results
None listed